Sulfonylureas up cardio events versus metformin

Sulfonylureas up cardio events versus metformin
Use of sulfonylureas for initial treatment of diabetes is associated with increased cardiovascular events and death compared with metformin, according to a study published in the Nov. 6 issue of the Annals of Internal Medicine.

(HealthDay)—Use of sulfonylureas for initial treatment of diabetes is associated with increased cardiovascular events and death compared with metformin, according to a study published in the Nov. 6 issue of the Annals of Internal Medicine.

Christianne L. Roumie, M.D., M.P.H., from the Veterans Affairs Tennessee Valley Healthcare System in Nashville, and colleagues conducted a to compare outcomes for 253,690 veterans who initiated metformin (155,025) or sulfonylurea (98,665) therapy for diabetes. The composite outcome consisted of hospitalization for or stroke, or death, adjusting for baseline demographic and medical characteristics.

The researchers found that crude rates for the composite outcome were 18.2 per 1,000 person-years in sulfonylurea users and 10.4 per 1,000 person-years in metformin users (adjusted incidence rate difference, 2.2 more cardiovascular events with sulfonylureas per 1,000 person-years; adjusted hazard ratio [aHR], 1.21). For both glyburide (aHR, 1.26) and glipizide (aHR, 1.15) results were consistent in subgroup analyses and in -matched cohort and sensitivity analyses.

"These observations support the use of metformin for first-line diabetes therapy and strengthen the evidence about the cardiovascular advantages of metformin compared with sulfonylureas," the authors write.

More information: Abstract
Full Text
Editorial

Related Stories

Popular diabetes meds put to the test

date Nov 06, 2012

(HealthDay)—Patients with diabetes who were treated with the popular oral medication metformin face a lower risk of heart attack, stroke or death than those taking sulfonylureas, another common option, ...

Recommended for you

US appeals court upholds delay in Alzheimer's drug swap

date May 22, 2015

A federal appeals court has rejected a drug manufacturer's appeal and affirmed a judge's order that Actavis PLC keep distributing its widely used Alzheimer's medication until after its patent expires this summer.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.